Skip to content
  1. Home
  2. >Test Catalog
  3. >Pharmacogenomics
  4. >Comprehensive Pharmacogenomics Pgx Panel
Back to catalog

Comprehensive Pharmacogenomics (PGx) Panel

Turnaround

6-9 days

Turnaround Requery

≤ 5 minutes

Panel Description

This test evaluates a patient’s metabolizer status for 27 genes, which can aid in appropriate medication selection and dosing to reduce risk of side effects and treatment failure for cancer, cardiovascular disease, pain, mental health and other conditions. Any information provided for drugs listed under "Limited Evidence Drug-Gene Associations" is provided for informational use only. For sections titled “Limited Evidence Drug-Gene Associations,” no interpretation of expected drug response is provided due to a lack of sufficient evidence and/or available guidelines.

View the complete description of this panel
Sample report

Have Questions?

Our team is available Monday through Friday, 9am-5pm Pacific Time.

(844) 211 2070clinicalsupport@helix.com

Genes Tested

ABCB1
ABCG2
ATIC
COMT
CYP2C cluster
CYP2C19
CYP2C9
CYP2D6
CYP3A4
CYP3A5
CYP4F2
DPYD
F2
F5
GRK4
HLA-B
IFNL3
IFNL4
MT-RNR1
MTHFR
NUDT15
OPRM1
SLC19A1
SLCO1B1
TPMT

Showing 25 of 27 genes in this panel

Other Tests to Consider

Test

Malignant Hyperthermia Susceptibility Panel

3

genes

Test

Pharmacogenomics (PGx) APOE Test

1

gene

Test

Pharmacogenomics (PGx) Fluoropyrimidines DPYD Test

1

gene

Test

Pharmacogenomics (PGx) Level A Panel

16

genes

Important Panel Information

Turnaround time: Typically 7-10 days (standard), Typically < 5 minutes (requery)

Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit

Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.

Patients for whom medication from the following list are being considered, have been ineffective, or caused side effects: Abacavir, Allopurinol, Amikacin, Amitriptyline, Amphetamine, Aripiprazole, Atomoxetine, Atorvastatin, Azathioprine, Brexpiprazole, Brivaracetam, Capecitabine, Carbamazepine, Celecoxib, Citalopram, Clobazam, Clomipramine, Clopidogrel, Clozapine, Codeine, Desipramine, Deutetrabenazine, Dexlansoprazole, Doxepin, Escitalopram, Flecainide, Flibanserin, Fluorouracil, Flurbiprofen, Fluvastatin, Fluvoxamine, Gefitinib, Gentamicin, Haloperidol, Hydrocodone, Ibuprofen, Iloperidone, Imipramine, Kanamycin, Lamotrigine, Lansoprazole, Lofexidine, Lornoxicam, Lovastatin, Meloxicam, Mercaptopurine, Metoprolol, Nortriptyline, Oliceridine, Omeprazole, Ondansetron, Oxcarbazepine, Pantoprazole, Paroxetine, Peginterferon alfa-2a, Peginterferon alfa-2b, Pimozide, Piroxicam, Pitavastatin, Plazomicin, Pravastatin, Propafenone, Quetiapine, Risperidone, Rosuvastatin, Sertraline, Simvastatin, Streptomycin, Tacrolimus, Tamoxifen, Tegafur, Tenoxicam, Thioguanine, Thioridazine, Tobramycin, Tramadol, Trimipramine, Tropisetron, Valbenazine, Venlafaxine, Voriconazole, Vortioxetine, and Warfarin

All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.